Shields Health Solutions

shieldshealthsolutions.com

One of the fastest growing companies in America, Shields Health Solutions partners with hospital leaders on every aspect of specialty pharmacy creation and growth. The company provides the fastest, lowest risk model for Hospital leaders to create and grow a hospital-owned specialty pharmacy business, whether starting from scratch or adding specialty capabilities to a hospital’s existing pharmacy programs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

ALGAENERGY AGREEMENTS WITH LABORATOIRE M2 FOR DISTRIBUTION AND PRODUCT DEVELOPMENT

AlgaEnergy | January 14, 2021

news image

AlgaEnergy N.A. Inc., the U.S. subsidiary of Spain-based AlgaEnergy S.A. furthermore, a worldwide pioneer in microalgae biotechnology, has marked worldwide item conveyance and item improvement concurrences with Laboratoire M2 Inc., a Quebec-based biotechnology organization that creates normal and practical disinfectant items, including THYMOX CONTROL® fungicide and bactericide. AlgaEnergy formulates and creates incredible, manageable, microalgae-based yield contributions for t...

Read More

TAVOTEK ANNOUNCES A RESEARCH AGREEMENT WITH GENMAB FOR THE DEVELOPMENT OF BISPECIFIC ANTIBODIES

Tavotek | May 25, 2020

news image

Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab's DuoBody® technology platform against disease relevant target antigens. Tavotek employs TavoSelect™, with proprietary VHO phage and Fab phage libraries, to efficiently identify lead molecules for generation of bispecific antibodies a...

Read More

AEGLE THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA FOR AGLE-102 FOR PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

Aegle Therapeutics | October 06, 2020

news image

Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD) Designation to AGLE-102™ for the treatment of dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerat...

Read More

CELL AND GENE THERAPY

CIMEIO THERAPEUTICS ANNOUNCES ISSUANCE OF KEY PATENT COVERING CELL THERAPY PLATFORM

Cimeio | November 29, 2022

news image

Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the U.S. Patent Office has issued a key patent covering the company’s Shielded-Cell & Immunotherapy Pairs platform. U.S. Patent No. 11,499,168 covers a method for in vivo selective depletion of edited primary hematopoietic cells or non-edited primary hematopoietic cells. This method was first discovered and developed in the lab of company founder Lukas Jeker, M.D.,...

Read More
news image

MEDICAL

ALGAENERGY AGREEMENTS WITH LABORATOIRE M2 FOR DISTRIBUTION AND PRODUCT DEVELOPMENT

AlgaEnergy | January 14, 2021

AlgaEnergy N.A. Inc., the U.S. subsidiary of Spain-based AlgaEnergy S.A. furthermore, a worldwide pioneer in microalgae biotechnology, has marked worldwide item conveyance and item improvement concurrences with Laboratoire M2 Inc., a Quebec-based biotechnology organization that creates normal and practical disinfectant items, including THYMOX CONTROL® fungicide and bactericide. AlgaEnergy formulates and creates incredible, manageable, microalgae-based yield contributions for t...

Read More
news image

TAVOTEK ANNOUNCES A RESEARCH AGREEMENT WITH GENMAB FOR THE DEVELOPMENT OF BISPECIFIC ANTIBODIES

Tavotek | May 25, 2020

Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab's DuoBody® technology platform against disease relevant target antigens. Tavotek employs TavoSelect™, with proprietary VHO phage and Fab phage libraries, to efficiently identify lead molecules for generation of bispecific antibodies a...

Read More
news image

AEGLE THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA FOR AGLE-102 FOR PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

Aegle Therapeutics | October 06, 2020

Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD) Designation to AGLE-102™ for the treatment of dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerat...

Read More
news image

CELL AND GENE THERAPY

CIMEIO THERAPEUTICS ANNOUNCES ISSUANCE OF KEY PATENT COVERING CELL THERAPY PLATFORM

Cimeio | November 29, 2022

Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, today announced the U.S. Patent Office has issued a key patent covering the company’s Shielded-Cell & Immunotherapy Pairs platform. U.S. Patent No. 11,499,168 covers a method for in vivo selective depletion of edited primary hematopoietic cells or non-edited primary hematopoietic cells. This method was first discovered and developed in the lab of company founder Lukas Jeker, M.D.,...

Read More